

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

August 13, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai - 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400 051. Script Code: WANBURY
---	---

Dear Sir/Madam,

Sub.: Press Release regarding EDQM Approval for new product Rivaroxaban API, USFDA DMF Clearances.

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Wanbury Limited received approval from the office of European Directorate for the Quality of Medicines and Healthcare (EDQM) for new product Rivaroxaban API recently which will enable to meet customer demand of EU and other countries accepting CEP.

The Company also received DMF clearance for Paraxetine HCI and for Metformin HCI from the office of USFDA while ANDA review for multiple customers.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd

Jitendra J. Gandhi
Company Secretary

